Advancements in cancer therapy include exploration of bispecific antibodies and antibody-drug conjugates as multifunctional therapeutics, highlighting a shift in drug development paradigms. Clinical trials investigate novel combinations such as gemcitabine, cisplatin, and durvalumab in biliary tract cancers, while new protein-drug conjugates target low mesothelin-expressing solid tumors. Phase I trials of Firsekibart, an anti-IL-1β monoclonal antibody, demonstrate safety and tolerability, heralding new options for inflammatory cancer modulation.